Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Synergetics USA Inc (NASDAQ: SURG) acted responsibly on behalf of investors’ profitability in the planned $110 million sale to Valeant Pharmaceuticals International Inc (NYSE: VRX). 

On September 2, 2015, Synergetics USA Inc (NASDAQ: SURG) and Valeant Pharmaceuticals International Inc (NYSE: VRX) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Valeant will acquire all outstanding shares of Synergetics' common stock for $6.50 per share in cash plus one contingent value right entitling the stockholder to receive up to $1.00 per share if specified sales thresholds for Synergetics are achieved following the closing. 

Based in O’Fallon, MO, Synergetics USA Inc is a medical device company serving the ophthalmology and neurosurgery markets in the United States and internationally.  Along with over 1000 products offered in the vitreoretinal surgical market the Company’s product lines focuses upon precision engineered disposable and reusable devices, surgical equipment, procedural kits, and the delivery of various energy modalities, including laser energy, ultrasonic energy, radio frequency energy for electro surgery and lesion generation, and visible light energy for illumination. 

The investigation focuses on whether NASDAQ: SURG investors received the highest price and whether the directors of Synergetics USA Inc acted in the best interest of Synergetics USA Inc company and its shareholders.   

If you purchased Synergetics USA Inc (NASDAQ: SURG) prior to September 2, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324. 

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185